Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib with Chemoradiation for HER2+ Esophagogastric Adenocarcinoma
NCT01769508Phase 2Terminated
- Sponsor
- SCRI Development Innovations
- Start
- Feb 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib in Esophago-Gastric Adenocarcinoma, sponsored by SCRI Development Innovations. Started Feb 2013; status: terminated.
02
Drugs
lapatinib
03
Conditions
Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on NCT01769508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01769508.